MARKUS PLOESSER: Open Payments
NPI 1669662755 · CHULA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$27,734 in 69 payments from 14 companies in 2025. Trend: 2023 $41,433 · 2024 $34,747 · 2025 $27,734
Speaker / faculty: $15,920Consulting: $7,460Food & beverage: $2,759Travel & lodging: $1,595
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 28 | $15,072 |
| Teva Pharmaceuticals USA, Inc. | 12 | $11,124 |
| Medtronic, Inc. | 5 | $349 |
| Neurocrine BioSciences, Inc. | 4 | $214 |
| Otsuka America Pharmaceutical, Inc. | 5 | $203 |
| Avanos Medical | 1 | $163 |
| Boston Scientific Corporation | 1 | $162 |
| Abbott Laboratories | 1 | $147 |
| E.R. Squibb & Sons, L.L.C. | 4 | $94 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
Products named: LYBALVI, UZEDY, ARISTADA, INGREZZA, REXULTI, SYNCHROMEDII, COOLIEF COOLED RADIOFREQUENCY, General - Pain Management.
Industry payments across CA — which companies pay providers there.
